Skip to main content

Generic Radicava ORS Availability

Last updated on Nov 7, 2023.

See also: Generic Radicava

Radicava ORS is a brand name of edaravone, approved by the FDA in the following formulation(s):

RADICAVA ORS (edaravone - suspension;oral)

  • Manufacturer: MITSUBISHI TANABE
    Approval date: May 12, 2022
    Strength(s): 105MG/5ML [RLD]

Has a generic version of Radicava ORS been approved?

No. There is currently no therapeutically equivalent version of Radicava ORS available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Radicava ORS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,987,341
    Issued: November 30, -0001

    Patent expiration dates:

    • November 1, 2039
      Drug product
  • Edaravone suspension for oral administration
    Patent 11,241,416
    Issued: February 8, 2022
    Inventor(s): Hayama Tetsuo & Takahashi Tomohiro & Omura Tomoyuki & Hayashi Kouji & Matsuda Munetomo & Miyazawa Tadashi

    An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

    Patent expiration dates:

    • November 1, 2039
      Drug product
  • Patent 11,478,450
    Issued: November 30, -0001

    Patent expiration dates:

    • November 1, 2039

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • May 12, 2025 - NEW PRODUCT


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.